Cognitive training for glioma patients with cognitive impairment
Application of Cognitive Training Based on Remind Strategy in Glioma Patients With Cognitive Impairment
This study tests if personalized brain training can help adults with glioma improve their thinking skills and quality of life compared to those who only receive standard care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 72 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | LanZhou University Academic / other |
| Locations | 1 site (Lanzhou, Gansu) |
| Trial ID | NCT06327048 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate cognitive outcomes in glioma patients by forming an interdisciplinary team that develops individualized cognitive training programs based on the Remind strategy. Adult patients diagnosed with glioma will be enrolled and divided into an intervention group receiving cognitive rehabilitation alongside standard care, and a control group receiving only standard care. Cognitive function, quality of life, and psychological status will be assessed at multiple time points during the study to determine the effectiveness of the intervention.
Who should consider this trial
Good fit: Ideal candidates are adult glioma patients with a MoCA score of 26 or lower and a Karnofsky Performance Status of 60 or higher.
Not a fit: Patients with neurological or psychiatric disorders, impaired consciousness, or severe complications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve cognitive function and quality of life for glioma patients experiencing cognitive impairment.
How similar studies have performed: While cognitive rehabilitation has been explored in various contexts, this specific application of the Remind strategy in glioma patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Conforming to the diagnostic criteria outlined in the "Chinese Clinical Guidelines for Diagnosis and Treatment of Central Nervous System Gliomas (2015)" ; 2. Patients diagnosed with brain gliomas through histopathological and/or cytological examination; 3. MoCA (Montreal Cognitive Assessment) score ≤ 26; 4. Karnofsky Performance Status (KPS) score ≥ 60, with no history of past illnesses; 5. Age ≥ 18 years; 6. Clear consciousness; 7. Willingness to participate and signed informed consent form. Exclusion Criteria: 1. Diagnosed with neurological or psychiatric disorders within the past two years; 2. Impaired consciousness; 3. Accompanied by severe complications such as infections; 4. Nursing Delirium Screening Checklist (Nu-DESC) score ≥ 2; 5. Patients with changes in condition or requiring repeat surgery; 6. Patients with multiple intracranial tumors; 7. Inability to effectively complete the questionnaire or withdrawal during the study.
Where this trial is running
Lanzhou, Gansu
- Yuanyuanma — Lanzhou, Gansu, China (Recruiting)
Study contacts
- Study coordinator: yuanyuan Ma
- Email: 1657107645@qq.com
- Phone: 18809406184
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.